Research
Combined treatment with lisofylline and exendin-4 reverses autoimmune
diabetes
Biochemical and Biophysical Research Communications; Copyright 2006
Elsevier, Inc.; Published April 5, 2006;
doi:10.1016/j.bbrc.2006.03.173
Activation of the 12-Lipoxygenase and Signal Transducer and Activator of
Transcription Pathway During Neointima Formation in a Model of the
Metabolic Syndrome -
Am J Physiol Endocrinol Metab (August 23, 2005).
doi:10.1152/ajpendo.00133.2005
Inflammatory Blockade Improves
Human Pancreatic Islet Function and Viability - American
Journal of Transplantation 2005; 5:475-483 Blackwell Munksgaard (PDF)
Inflammation blockade improves pancreatic islet function -
Transplant Proc. 2004 Nov;36(9):2864-5.
Autoimmune diabetes is blocked in Stat4-deficient mice -
J Autoimmun. 2004 May;22(3):191-200.
Lisofylline, a novel anti-inflammatory agent, enhances
glucose-stimulated insulin secretion in vivo and in vitro: studies in
prediabetic and normal rats -
Metabolism.
2004 Mar;53(3):290-6.
The novel anti-inflammatory agent lisofylline prevents autoimmune
diabetic recurrence after islet transplantation -
Transplantation.
2004 Jan 15;77(1):55-60.
Lisofylline, a Novel Antiinflammatory Compound, Protects Mesangial Cells
from Hyperglycemia- and Angiotensin II-Mediated Extracellular Matrix
Deposition - Endocrinology Vol. 144, No. 12
5227-5231
Copyright © 2003 by The Endocrine Society
The novel anti-inflammatory compound, lisofylline, prevents diabetes
in multiple low-dose streptozotocin-treated mice -
Pancreas. 2003
May;26(4):e99-104.
Lisofylline,
a Novel Antiinflammatory Agent, Protects Pancreatic ß-Cells from
Proinflammatory Cytokine Damage by Promoting Mitochondrial Metabolism
- Endocrinology Vol. 143, No. 6
2341-2348
Copyright © 2002 by The Endocrine Society
The anti-inflammatory compound lisofylline prevents Type I diabetes
in non-obese diabetic mice -
Diabetologia. 2002 Sep;45(9):1307-14.
Epub 2002 Aug 1
Documents in PDF format require the Free Adobe Reader
|
